bevacizumab
View Patient InformationA recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
| Synonym: | anti-VEGF humanized monoclonal antibody anti-VEGF monoclonal antibody SIBP04 anti-VEGF rhuMAb BAT1706 biosimilar bevacizumab awwb bevacizumab biosimilar ABP 215 bevacizumab biosimilar BAT1706 bevacizumab biosimilar BEVZ92 bevacizumab biosimilar BI 695502 bevacizumab biosimilar CBT 124 bevacizumab biosimilar CT-P16 bevacizumab biosimilar FKB238 bevacizumab biosimilar GB-222 bevacizumab biosimilar HD204 bevacizumab biosimilar HLX04 bevacizumab biosimilar IBI305 bevacizumab biosimilar LY01008 bevacizumab biosimilar MIL60 bevacizumab biosimilar Mvasi bevacizumab biosimilar MYL-1402O bevacizumab biosimilar QL 1101 bevacizumab biosimilar QL1101 bevacizumab biosimilar RPH-001 bevacizumab biosimilar SCT501 bevacizumab biosimilar Zirabev bevacizumab-adcd bevacizumab-maly BP102 biosimilar immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMab-VEGF light chain, dimer recombinant humanized anti-VEGF monoclonal antibody |
|---|---|
| US brand name: | Alymsys Avastin Jobevne Mvasi Zirabev |
| Foreign brand name: | Vegzelma |
| Abbreviation: | rhuMab-VEGF |
| Code name: | ABP 215 BAT 1706 BAT-1706 BAT1706 BP102 CT-P16 HD204 MYL-1402O QL1101 SCT501 SIBP 04 SIBP-04 SIBP04 |